PRA Health Sciences, Inc. (PRAH)
(Delayed Data from NSDQ)
$93.38 USD
+1.38 (1.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $93.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.38 USD
+1.38 (1.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $93.43 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens
by Zacks Equity Research
PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.
Is Another Great Depression Imminent or Is it Just a Myth?
by Urmimala Biswas
Asian countries have already shown clear signs of major economic recession.
3 Remote Patient Monitoring Stocks in Focus Amid Coronavirus
by Sriparna Ghosal
In the wake of the pandemic, the remote patient monitoring space continues to thrive on a number of positive developments.
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
by Zacks Equity Research
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Why Is PRA Health Sciences (PRAH) Down 9.1% Since Last Earnings Report?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRA Health (PRAH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.
Analysts Estimate PRA Health Sciences (PRAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Digital HealthCare Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
In the face of the pandemic, the digital health management space continues to thrive on a number of positive developments.
PRA Health Boosts Health Harmony COVID-19 Monitoring Program
by Zacks Equity Research
PRA Health (PRAH) gives a boost to COVID-19 Monitoring program through collaboration with the Microsoft Healthcare Bot service.
Why Is PRA Health Sciences (PRAH) Up 7.3% Since Last Earnings Report?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.
PRA Health Sciences (PRAH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.96% and 3.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will PRA Health Sciences (PRAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
PRA Health Sciences (PRAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why PRA Health (PRAH) Might Surprise This Earnings Season
by Zacks Equity Research
PRA Health (PRAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Earnings Preview: PRA Health Sciences (PRAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coronavirus Puts Digital Health in Focus: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are focusing on digital health to fight against coronavirus.
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
by Zacks Equity Research
PRA Health's (PRAH) new module is likely to boost Data Solutions segment.
OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
PRA Health's New Program to Lend Support to Healthcare System
by Zacks Equity Research
PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.
OPKO's BioReference Laboratories Offers COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
Why Is PRA Health Sciences (PRAH) Down 39.4% Since Last Earnings Report?
by Zacks Equity Research
PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRA Health (PRAH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Solid Clinical Research revenues drove PRA Health's (PRAH) Q4 results.
Here's Why You Should Retain PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.
PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.
PRA Health Sciences (PRAH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 1.54% and 1.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?